NetraMark's AI Mental Health Insights, Nona's Antibody Discovery, and Freed's $30M Scribing Boost - Life AI Weekly #8

Hi there,

In this week's edition of Life AI Weekly, we're diving into the latest advancements in AI within the healthcare and life sciences sectors. NetraMark is showcasing its AI insights for mental health at the ISCTM, while Nona Biosciences has launched a new AI-powered platform aimed at revolutionizing antibody discovery. Meanwhile, Tethis and Sheba Medical Center are collaborating on an AI liquid biopsy for cancer, promising to enhance early detection and treatment strategies.

On the business front, XUND has raised €6 million to expand its AI healthcare solutions, and Freed secured $30 million to enhance AI medical scribing. In healthcare tech, the NHS has launched an AI framework to ensure safe AI use in London, and RamSoft has partnered with CARPL.ai to integrate AI into radiology. These developments highlight the growing impact of AI in transforming healthcare delivery and research.

XUND has raised €6 million to expand its AI healthcare solutions in Europe, targeting the DACH region and the UK. Freed secured $30 million from Sequoia Capital to enhance its AI medical scribing services. Peak XV Partners invested $33 million in Luminai to automate healthcare operations. moveUP acquired Deep Structure.ai to improve AI-driven orthopedic care. Suvoda LLC launched Sofia, an AI assistant for clinical trial management.

NetraMark Holdings Inc. presented studies at the ISCTM conference, demonstrating the use of its AI technology, NetraAI, to enhance clinical trial outcomes for major depressive disorder and schizophrenia. Nona Biosciences has introduced the AI-assisted Hu-mAtrIxTM platform to enhance antibody discovery, integrating with its Harbour Mice® technology to accelerate research in neurodegenerative and metabolic diseases. Tethis S.p.A. and Sheba Medical Center have partnered to research AI-powered liquid biopsy technology for monitoring rectal cancer, focusing on predicting relapse through CTCs and ctDNA analysis. The Coalition for Epidemic Preparedness Innovations (CEPI) has allocated up to 750 million JPY to Nagasaki University for developing vaccines against Severe Fever with Thrombocytopenia Syndrome (SFTS) using the Nanoball platform and NEC's AI. Researchers at Pusan National University have created the Hypergraph Interaction Transformer (HIT), an AI model that enhances the discovery of therapeutic gene targets by using hypergraphs and attention-based learning.

ARUP Laboratories expands its AI tool for parasite screening to include wet-mount slides, enhancing accuracy in ova and parasite testing. Body Vision Medical receives Australian approval for its AI-powered LungVision system, improving lung cancer diagnosis. Caristo Diagnostics gains FDA clearance for its AI tech, CaRi-Plaque, to enhance coronary artery disease detection.